Ivor Royston's most recent trade in Viracta Therapeutics Inc was a trade of 25,219 Common Stock done . Disclosure was reported to the exchange on Nov. 25, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 25,219 | 839,741 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Royston Ivor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 25,219 | 50,438 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2024 | 25,219 | 814,522 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2024 | 25,219 | 75,657 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 25,219 | 789,303 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2024 | 25,219 | 100,876 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Royston Ivor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 25,219 | 126,095 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Royston Ivor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 25,219 | 764,084 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 25,219 | 176,533 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 25,219 | 713,646 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 25,219 | 663,208 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 25,219 | 226,971 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 25,219 | 637,989 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 25,219 | 252,190 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 25,219 | 626,149 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 25,219 | 277,409 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 4.01 per share. | 25 Aug 2022 | 13,379 | 612,770 | - | 4.0 | 53,656 | Common Stock |
| Biocept Inc | Ivor Royston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2022 | 10,000 | 10,000 | - | - | Employee Stock Option (right to buy) | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 25,219 | 302,628 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 25,219 | 614,092 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 1.90 per share. | 25 May 2022 | 13,162 | 600,930 | - | 1.9 | 25,022 | Common Stock |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 412,500 | 412,500 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 25,219 | 603,508 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 25,219 | 327,847 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 2.78 per share. | 25 Feb 2022 | 14,635 | 588,873 | - | 2.8 | 40,678 | Common Stock |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 29 Dec 2021 | 7,000 | 578,289 | - | 0.9 | 6,300 | Common Stock |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2021 | 7,000 | 60,800 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 50,437 | 599,036 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 50,437 | 353,066 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 4.82 per share. | 25 Nov 2021 | 15,833 | 571,289 | - | 4.8 | 76,301 | Common Stock |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 25 Nov 2021 | 11,914 | 587,122 | - | 4.8 | 57,194 | Common Stock |
| Viracta Therapeutics Inc | Ivor Royston | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 5.56 per share. | 15 Nov 2021 | 8,000 | 548,599 | - | 5.6 | 44,480 | Common Stock |
| Biocept Inc | Ivor Royston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2021 | 10,000 | 10,000 | - | - | Employee Stock Option (right to buy) |